Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.
Molecular Partners aims to test a COVID-19 drug candidate on people during 2020, Chief Executive Patrick Amstutz said, as the Swiss company hopes that project will help it recover from the failure of the eye drug abicipar.
Sosei Group entered a discovery collaboration and licensing deal with AbbVie, initially focused on inflammatory and autoimmune diseases.
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
AstraZeneca signed a tenth supply-and-manufacturing deal for the company’s experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.
Alpine Immune Sciences shares exploded 211 percent in premarket trading at news of a global option and license deal with AbbVie.
As AstraZeneca closes in on developing a vaccine against COVID-19, the U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020.
Emergent BioSolutions signed an $87 million deal to make AstraZeneca’s experimental COVID-19 vaccine in the United States.
GlaxoSmithKline inked deals earlier this year to support the development of multiple adjuvanted COVID-19 vaccine candidates and has now pledged to manufacture 1 billion doses of that efficacy-boosting system by 2021.
Merck exploded into the COVID-19 battle with three significant deals and collaborations.
